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(57) ABSTRACT 
Procedures and methods for synthesizing biodegradable 
polymer coated nanoceria result in stable nanoparticle prepa-
rations in aqueous systems and physiological relevant colloi-
dal solutions, such as phosphate buffer saline. The coated 
nanoceria preparations increase the nanoparticle concentra-
tion in aqueous or colloidal solutions as most needed for 
antioxidant, free-radical scavenger, and autocatalytic bio-
medical applications, including, biological, pharmacological 
and potential clinical use. To meet this need, a facile synthetic 
procedure for preparation of a biodegradable polymer-coated 
nanoceria is disclosed; the preferred biodegradable polymer 
is dextran. The synthesis method occurs under ambient con-
ditions in an aqueous phase without the use of surfactants and 
results in a monodispersed preparation that is dextran-coated 
as determined by dynamic light scattering (DLS). Prelimi-
nary characterization of polymer coated nanoceria by XPS, 
TEM, XRD, and the like shows that these nanoparticles have 
the necessary physical properties for the desired biological 
potency, such as Ce+4 /Ce+3 mixed valence state. 
25 Claims, 14 Drawing Sheets 
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Fig. 6B 
Photographic image of 
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SYNTHESIS OF POLYMER COATED CERIA 
NANOPARTICLES FOR BIOMEDICAL 
APPLICATIONS 
The present application claims the benefit of priority from 
U.S. Provisional Patent Application Ser. No. 60/878,043 filed 
on Dec. 29, 2006, which is incorporated herein by reference. 
FIELD OF THE INVENTION 
This invention relates to biological uses of nanoceria par-
ticles, and in particular to methods and compositions useful in 
the synthesis of polymer coated ceria oxide nanoparticles for 
biomedical applications. 
BACKGROUND AND PRIOR ART 
2 
ing cerium oxide, some of which are associated with a poly-
mer, including dextran. The colloidal compositions are useful 
as imaging agents in technology requiring injectable chemi-
cals for contrast agents. There is no mention of cerium oxide 
coated with polymers having autocatalytic and antioxidant 
properties. 
U.S. Patent Publication 2006/0142749 to Robert Ivkov 
discloses thermotherapeutic compositions for treating dis-
ease. The thermotherapeutic compositions include magnetic 
10 nanoparticles that may be coated to enhance the heating prop-
erties of a bioprobe, particularly if the coating is a polymeric 
material that can include dextran. 
Thus, polymeric coatings including dextran have been 
reported for use on magnetic nanoparticles and the results 
15 seem promising in molecular imaging, monitoring and thera-
peutic treatment of disease. 
It is desirable to find reliable solutions to use of nanoceria 
Cerium is a silvery metallic element, belonging to the 
lanthanide group. Cerium oxide (Ce02 ) is used in precision 
polishing and lapping applications. Ultra fine nano-size 20 
cerium oxide, less than 10 nanometers, is more efficient for 
coating purposes. Recently, it was reported by B. Rzigalinski 
particles with antioxidant properties in the treatment of many 
human diseases that are due to the death of cells in specific 
tissues or organs. The majority of those diseases are due to 
accumulation of metabolic insults from reactive oxygen spe-
cies originating within or outside of the cells. These diseases 
include all forms of blindness whether hereditary, light-in-
duced, or physical damage such as occurs in retinal detach-
ment. In addition, damage due to ageing, stroke, cardiac 
infarction, bums, etc, which proceed through reactive oxygen 
et al. that nanoparticles prolong the life of cortical neurons in 
culture 4 fold over the cells without treatment, decrease the 
intracellular Ca2+ concentration and prevent UV damage of 25 
cortical neurons. See B. Rzigalinski et al., "Cerium Oxide 
Nanoparticles Extend Cell Longevity and Act as Free Radical 
Scavengers" at website www.med.miami.edu/nmbws/Rziga-
linski 112. Based on its chemical characteristics, this effect is 
partially due to a decrease of reactive oxygen species (ROS). 30 
species, can be addressed with the nanoceria particles syn-
thesized according the present invention. 
SUMMARY OF THE INVENTION 
Various investigators have shown that nanoceria particles 
possess antioxidant properties and have demonstrated sur-
vival of neuron cells in cultures against oxidative stress and 
radiation. The greatest benefit of the nanoceria is its ability to 
get inside the cells and provide protection from reactive oxy- 35 
gen species (ROS); other body systems and tissues can also be 
protected from damage due to ROS. 
A primary objective of the present invention is to provide a 
facile, synthetic method for the formation of cerium oxide 
(ceria) nanoparticles coated with a biodegradable polymer. 
A secondary objective of the present invention is to provide 
a synthetic method for the formation of cerium oxide ( ceria) 
nanoparticles coated with dextran, a biodegradable polymer 
that can be scaled up for commercial production. However, the synthetic procedures for nanoceria reported 
so far are not likely to be approved by the U.S. Food and Drug 
Administration (FDA) because the synthesis procedures 40 
involve the use of surfactants and other toxic materials. 
A third objective of the present invention is to provide 
cerium oxide (ceria) nanoparticles coated with a biodegrad-
able polymer that has physical properties that are substan-
tially identical of the properties of uncoated nanoceria par-
ticles for therapeutic applications. 
In addition to the use of non-approved surfactants and toxic 
materials, the published synthetic methods result in uncoated 
nanoparticles which agglomerate in aqueous solution. 
Further developments in biomedical research reveal the 
efficacy of coated magnetic nanoscale particle compositions 
for therapeutic uses. In Patent Publication W0/2003/005029 
to Zhenghe Xu et al. iron and iron oxide particles are coated 
with dextran for biological cell separation using magnetic 
carrier technology. The dextran coating is used to prevent 
mechanical instability of the particle in suspension. 
U.S. Patent Publication 2003/0124,194 to Gaw et al. dis-
closes amine functionalized superparamagnetic nanopar-
ticles using a process that consists of coating magnetic nano-
particles with a carboxylated polymer then subsequently 
reacting the carboxylated functionalized magnetic nanopar-
ticles with carbodiimide and a large excess of diamine, after 
which the amine-terminated nanoparticles are reacted with 
bifunctional crosslinking agents and with various biomol-
ecules. 
U.S. Patent Publication 2005/0130167 to Gang Boa, et al. 
provides multifunctional magnetic nanoparticle probe com-
positions for molecular imaging and monitoring wherein the 
magnetic nanoparticle has a biocompatible coating, such as, 
dextran, thereon. 
U.S. Patent Publication 2006/0014938 to Groman et al. 
describes stable aqueous colloidal lanthanide oxides, includ-
A fourth objective of the present invention is to provide 
45 cerium oxide (ceria) nanoparticles coated with a biodegrad-
able polymer with good solubility and stability in water and 
phosphate buffer saline. 
A fifth objective of the present invention is to provide a 
facile, synthetic method for the formation of cerium oxide 
50 (ceria) nanoparticles coated with dextran that is further 
crosslinked with epichlorohydrin and ammonia, resulting in 
an aminated dextran coated ceria nanoparticles to create a 
targetable ceria nanoparticle. 
A sixth objective of the present invention is to provide a 
55 water stable, biodegradable polymer coated nanoceria prepa-
ration that is biologically active for administration to human 
and other manimals. 
A seventh objective of the present invention is to provide a 
water stable, biodegradable polymer coated nanoceria prepa-
60 ration that has a long circulation time, such as, a plasma 
half-life longer than one minute. 
An eighth objective of the present invention is to provide a 
facile, synthetic method for the formation of cerium oxide 
(ceria) nanoparticles coated with polyacrylic or any other 
65 polycarboxylic acid polymer that will result in a carboxyl 
group functionalized nanoparticle. The ceria nanoparticles 
coated with functionalized car boxy 1 groups are reacted with a 
US 8,333,993 Bl 
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diamine, such as ethylenediamine, to create an amine func-
tionalized cerium oxide nanoparticle without the need for 
polymeric crosslinking. 
A preferred method for the synthesis of a plurality of 
cerium oxide nanoparticles coated with a biodegradable poly-
mer for antioxidant, free-radical scavenging and autocatalytic 
biomedical applications, includes preparing an aqueous 
cerium nitrate solution, mixing the aqueous cerium nitrate 
solution with a biodegradable polymer to form a first mixture, 
adding the first mixture dropwise to an ammonium hydroxide 10 
solution while continuously stirring to form a second mixture, 
centrifuging the second mixture containing ammonium 
hydroxide to settle any debris or large particles, purifying the 
centrifuged mixture by ultrafiltration, and recovering a plu-
15 
rality of non-agglomerated cerium oxide nanoparticles 
coated with the biodegradable polymer wherein the antioxi-
dant, free-radical scavenging and autocatalytic properties of 
the cerium oxide nanoparticles are unchanged from uncoated 
cerium oxide nanoparticles. 20 
The preferred synthesis method has a biodegradable poly-
mer that is at least one of a carbohydrate polymer, a synthetic 
polyol, a carboxylated polymer, and derivatives thereof, more 
preferably, the carboxylated polymer is polyacrylic acid. 
It is also preferred that the carboxylated polymer is reacted 25 
with a diamine selected from at least one of ethylene diamine, 
propylene diamine and hexane diamine, to provide an ami-
nated cerium oxide nanoparticle in a reaction that eliminates 
the need for polymer crosslinking. 
The preferred carbohydrate polymer for the synthesis 30 
method of the present invention is a polysaccharide, such as 
dextran, arabinogalactan, chitosan and the like; most prefer-
ably the polysaccharide is dextran. 
In the preferred synthesis method the cerium nitrate solu-
tion contains approximately 2.0 to approximately 3.0 grams 35 
of cerium nitrate to approximately 5 ml of water and the 
plurality of dextran-coated cerium oxide nanoparticles has a 
UV profile exhibiting strong absorption below approximately 
400 nm with peak absorption at approximately 300 nm. 
A preferred composition that is useful as a potent antioxi- 40 
dant in biomedical applications includes a plurality of nano-
ceria particles coated with a biodegradable polymer selected 
from at least one of a carbohydrate polymer, a synthetic 
polyol, a carboxylated polymer, and derivatives thereof. The 
more preferred carboxylated polymer is polyacrylic acid. The 45 
preferred carbohydrate polymer is a polysaccharide, such as, 
dextran, arabinogalactan and chitosan; most preferably, the 
polysaccharide is dextran. 
In the preferred composition, the plurality of dextran-
coated cerium oxide nanoparticles has a UV profile exhibit- 50 
ing strong absorption below approximately 400 nm with peak 
absorption at approximately 300 nm and the physical prop-
erties of the dextran-coated cerium nanoparticles replicate the 
physical properties of the uncoated nanoceria particles for 
therapeutic applications as antioxidants, free-radical scaven- 55 
gers and autocatalytic agents. 
4 
ride such as, dextran, arabinogalactan and chitosan; the most 
preferred polysaccharide is dextran. 
The preferred composition has a plurality of dextran-
coated cerium oxide nanoparticles with a UV profile exhib-
iting strong absorption below approximately 400 nm with 
peak absorption at approximately 300 nm and the physical 
properties of the dextran-coated cerium nanoparticles repli-
cate the physical properties of the uncoated nanoceria par-
ticles for therapeutic applications as antioxidants, free-radi-
cal scavengers and autocatalytic agents. 
The more preferred composition has a plurality of dextran-
coated cerium oxide nanoparticles that form a colloidal sus-
pension that is stable in water and also form a colloidal 
suspension that is stable in a phosphate buffer saline solution. 
Further objects and advantages of the present invention 
will be apparent from the following detailed description of a 
presently preferred embodiment which is illustrated sche-
matically in the accompanying drawings. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 shows the UV-visible absorption spectrum of the 
dextran coated nanoceria prepared in the present invention. 
FIG. 2 is the fluorescence spectra of dextran coated cerium 
oxide nanoparticle O'-ex =283 nm) showing a characteristic 
fluorescence peak at approximately 410 nanometer (nm) 
wavelength. 
FIG. 3 shows the measurement of zeta-potential in the 
analysis of the stability of nanoparticle preparation against 
agglomeration within biological systems. 
FIG. 4 shows the X-ray diffraction pattern ofnanocrystal-
line cerium oxide coated with dextran in the present inven-
tion. 
FIG. 5 shows the X-ray photon spectroscopy spectrum of 
the synthesized cerium oxide nanoparticles coated with dex-
tran showing the presence of a mixed valence (Ce3+ and 
Ce4+) state. 
FIG. 6A is a photographic image of a first solution of 
dextran coated nanoceria after ultrafiltration with an Amicon 
30 K filter. 
FIG. 6B is a photographic image of a second solution of 
dextran coated nanoceria after the solution is concentrated 
using a 30K Centricon concentrator. 
FIG. 7A is a transmission electron microscopy (TEM) 
image of the dextran coated ceria nanoparticles showing the 
size and dispersity of the ceria crystals. 
FIG. 7B is a high resolution transmission electron micros-
copy (HRTEM) image of the dextran coated ceria nanopar-
ticles showing that the coating does not affect the crystallin-
ity. 
FIG. 7C is a selected area electron diffraction (SAED) 
image of a single ceria crystal showing that the dextran coated 
ceria crystal is a face-centered cubic (FCC) phase crystal. 
FIG. 8 is a graph showing the increase in particle size with 
time on concanavalin addition. 
FIG. 9 is a graph showing reversible and successive shift in 
transmittance of dextran coated nanoceria particles after add-
ing hydrogen peroxide (Days 1-10). 
In the preferred composition, the plurality of dextran-
coated cerium oxide nanoparticles form a colloidal suspen-
sion that is stable in water and form a colloidal suspension 
that is stable in a phosphate buffer saline solution. 
FIG. lOA is a real-time image of dextran nanoceria solu-
60 tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day one. A more preferred composition of matter that is useful as an 
antioxidant, free-radical scavenger and autocatalyst in bio-
medical applications includes a plurality of nanoceria par-
ticles coated with a crosslinked-aminated biodegradable 
polymer selected from at least one of a carbohydrate polymer, 65 
a synthetic polyol, a carboxylated polymer, and derivatives 
thereof. The preferred carbohydrate polymer is a polysaccha-
FIG. lOB is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day three. 
FIG. lOC is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day seven. 
US 8,333,993 Bl 
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FIG. lOD is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day ten. 
FIG. lOE is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day ten after adding fresh hydro-
gen peroxide. 
6 
The first embodiment of the present invention provides a 
method and procedure for synthesizing a biodegradable poly-
mer coated ceria nanoparticle for antioxidant and autocata-
lytic biomedical applications. 
The second embodiment of the present invention provides 
a method and procedure for synthesizing aminated cross-
linked dextran coated ceria nanoparticles for antioxidant and 
autocatalytic biomedical applications. 
The third embodiment of the present invention provides a 
FIG. lOF is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day twenty. 
FIG. llA is a graph showing the percent viability ofnormal 
cardiomyocyte cell cultures untreated and treated with dext-
ran coated nanoparticles, hydrogen peroxide and a combina-
tion of dextran coated nanoparticles and hydrogen peroxide. 
10 method and procedure for synthesizing non-crosslinked, car-
boxylated polymer coated ceria nanoparticles to provide an 
amine functionalized nanoparticle for antioxidant and auto-
catalytic biomedical applications. 
FIG. llB is a graph showing the percent viability ofnormal 
dermal fibroblasts cell cultures untreated and treated with 
dextran coated nanoparticles, hydrogen peroxide and a com-
bination of dextran coated nanoparticles and hydrogenperox-
ide. 
The examples below provide further detail on the synthesis 
15 and physical characterization of the biodegradable polymer 
coated ceria nanoparticles of the present invention. 
FIG. 12 is an X-ray photon spectroscopy (XPS) spectra of 
the aminated nanoceria showing the presence of a mixed 
valence, ce+3 and ce+4 similar to the spectrum of dextran 
coated nanoceria that is not aminated. 
20 
FIG. 13 is an X-ray photon spectroscopy (XPS) spectrum 25 
of the polyacrylic acid coated nanoceria (PAA-nanoceria) 
showing the presence of a mixed valence, ce+3 and ce+4 
similar to the spectrum of dextran coated nanoceria and ami-
nated dextran coated nanoceria shown in FIG. 12. 
Example 1 
Synthesis ofDextran Coated Ceria Nanoparticles 
Under ambient conditions, a 1 M cerium nitrate solution 
(2.17 gin 5 ml of water) was mixed with a IM Dextran T-10 
( 5 g in 10 ml of water) to form mixture (I). Under continuous 
stirring, the mixture (I) is then added dropwise to 30 ml of 
29% animonium hydroxide solution (Fischer, USA) forming 
mixture (II). Mixture (II) is then stirred continuously for 24 
hours. After 24 hours of stirring, the solution turns from a 
light yellow to a deep brown color. The preparation is centri-
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
30 fuged at a rate of 4000 rpm for two 30-minute cycles to settle 
down any debris and large particles. The preparation is then 
purified from free dextran by ultrafiltration using a 30 K 
Amicon filter. 
Before explaining the disclosed embodiments of the 
present invention in detail it is to be understood that the 35 
invention is not limited in its application to the details of the 
particular arrangements shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
The term "nanoceria" is used interchangeably with 40 
"cerium oxide nanoparticles" and is used to refer to the 
cerium oxide particles of multiple valences. 
The term "biodegradable polymer" is used herein to 
describe a class of polymers that are non-toxic to mammals 
and the environment and more specifically, include dextran, 45 
derivatives of dextran such as reduced dextran, carboxyl 
methyl reduced dextran, a polyol polymer or carbohydtrate 
polymer, synthetic polyols, carboxylated polymers, such as 
polyacrylic acid, and other polysaccharides, such as, but not 
limited to, arabinogalactan, and chitosan as disclosed in Gro- 50 
man et al. U.S. Patent Publication 2006/0014938 and Gaw et 
al. U.S. Patent Publication 2003/0124,194. 
In the present invention, the cerium oxide nanoparticles or 
nanoceria are polymer associated, or, in other words, coated 
with a biodegradable polymer. The polymer confers stability 55 
in water and can be functionalized with carboxylic or amino 
groups for conjugation with proteins, peptides, oligonucle-
otides, small molecules, and the like. 
Example 2 
Crosslinking and Amination of Dextran Coated Ceria 
with Epichlorohydrin 
Dextran coated ceria nanoparticles are crosslinked with 
epichlorohydrin using following procedure under ambient 
conditions: 
To 3 ml (3 volume) of dextran coated nanoceria particle 
preparation in Example 1, 5 mL (5 volumes) of5MNaOHare 
added while stirring. Then, 2 mL (2 volumes) of epichloro-
hydrin are added to the stirring solution. The ceria nanopar-
ticle suspension is stirred vigorously for 8 hours at room 
temperature. Then, 8.5 mL (8.5 volumes) of30% ammonia is 
added and stirred overnight at room temperature. The next 
day, the excess epichlorohydrin and ammonia are removed by 
ultrafiltration and the nanoparticle buffer is exchanged to 
0.025 M Na-Citrate buffer pH 8. At this point, the aminated 
dextran nanoceria preparation can be concentrated without 
precipitation of the nanoparticles. 
Epichlorohydrin is used as the crosslinking agent in 
Example 2, however, it is understood by those skilled in the 
art that other crosslinking agents may be used, such as glut-
araldehyde, bromide derivatives of cyanogens and the like. 
It is a primary concern that the physical properties of the 
biodegradable polymer coated ceria nanoparticles remain 
unaffected by the coating which improves handling and appli-
cation for biomedical purposes. 
In general, the polymer coated nanoceria particles of the 
present invention each have a size between approximately 1 60 
nanometer (nm) to approximately 500 nm in diameter, pref-
erably between approximately 1 nm and approximately 10 
nm. In FIG. 1, the UV profile for the dextran coated nanoceria 
is shown. Dextran coated ceria particles show strong absorp-
65 ti on below 400 nm with peak absorption maximum at 300 nm. 
Methods of preparing the biodegradable polymer coated 
cerium oxide compositions for use as an antioxidant and 
protection from damaging ultra violet (UV) radiation are 
provided in detail below. 
The UV profile of the dextran coated nanoceria prepared in 
the present invention is similar to that obtained in previous 
US 8,333,993 Bl 
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work showing that naked or uncoated ceria nanoparticles 
have well defined peak absorption around 305 run. Thus, the 
UV profile of the coated and uncoated nanoceria is substan-
tially the same. 
In FIG. 2 the fluorescence spectra of dextran coated nano-
ceria particles of the present invention has a characteristic 
fluorescence peak around 410 run and is similar to the fluo-
rescence spectra of the uncoated nanoceria particles reported 
by S. Sathyamurthy et al. in "Reverse Micellar Synthesis of 
Cerium Oxide Nanoparticles" Nanotechnology 16 (2005) 
1960-1964. 
To analyze the stability of nanoparticle preparation against 
agglomeration within biological systems, zeta-potential mea-
surement is performed. In pure water, the zeta-potential mea-
surements of oxide dispersions cover a wide range from -25 
8 
Concanavalin is a protein with four binding sites, known to 
bind carbohydrates. This protein has been used to induce the 
clustering of dextran-coated gold nanoparticles and most 
recently it was used in clustering iron oxide nanoparticles. It 
is used to study how the clustering phenomenon changes the 
optical (gold nanoparticles ), or magnetic (iron oxide) prop-
erties of the nanoparticles. It is used to verify whether the 
dextran is associated to (coating) the nanoparticle. In these 
studies, dextran coated nanoceria is incubated with con-
lO canavalin and an increase in the particle size is observed as 
measured by dynamic light scattering (DLS). This increase in 
"size" by light scattering is not due to an increase in the size 
of the nanoparticles, but rather is due to the clustering of the 
15 
nanoparticles in solution. FIG. 8 shows that after 90 minutes 
incubation with concanavalin, nanoparticle clusters of 650 
run in size are observed thus, showing the increase in particle 
size with time on concanavalin addition. 
to 55 mV. Due to the presence of dextran polymer on the 
surface of the nanoparticle, its charge distribution would be 
affected and the zeta potential would be shifted toward more 
positive and less negative values. The dextran coated nanoc-
eria preparation of the present invention has a zeta potential of 20 
-5.7 mV as shown in FIG. 3. 
Autocatalytic behavior of dextran-coated nanoceria was 
studied with addition of hydrogen peroxide. One of the most 
interesting properties ofnanoceria is its autocatalytic behav-
ior. The ability of these nanoparticles to reversibly switch 
from Ce+3 to Ce+4 , is a key factor for their biological appli-
cations as an antioxidant, among others. Therefore, it is deter-
The X-ray diffraction (XRD) pattern for the dextran coated 
nanoceria is shown in FIG. 4. The diffraction peaks found in 
the coated nanoceria are in a good agreement with those 
found in bulk ceria and preparation of uncoated nanoceria, as 
determined by the earlier investigator (W. Chengyun et al, 
2002, S. Sathyamurthy et al, 2005). The broadening of the 
peak suggests that the particles are of small dimension. The 
particle size, which can be calculated using the Scherrer 
equation, is around 3 run, which is in agreement with the data 
obtained by TEM. Also XRD confirms that it has (111 ), (220), 
(311) and (331) plane which was compared with the data 
obtained the JCPDF file. 
X-ray photon spectroscopy (XPS) data in FIG. 5 show the 
presence of a mixed valence state, indicating that the dextran 
coating on the nanoparticle does not affect this key physical 
property of nanoceria. The data also show that the amount of 
Ce+3 ion in the nanoparticle is more than the amount of Ce+4 
ion, in agreement with the small particle size (of less than 5 
run) as reported by D. Schubert et al., Biochemical and Bio-
physical Research Communications 2006, 342, 86. 
FIG. 6A is a photographic image of a sample of dextran 
nanoceria in aqueous solution wherein the vial on the left 
corresponds to a solution of dextran nanoceria obtained fol-
lowing the procedure we are disclosing in this invention dis-
closure, after ultrafiltration with an Amicon 30 K filter as 
described in Example 1. When a sample of this solution is 
concentrated using a 30K Centricon concentrator, a more 
concentrated dextran coated nanoceria is obtained, as shown 
25 mined whether the dextran coating on the nanoceria prepara-
tion compromised its autocatalytic behavior. In these 
experiments, the nanoparticles are oxidized using hydrogen 
peroxide. It is observed that after adding hydrogen peroxide 
to the nanoceria there is a red shift and also color changes to 
30 dark brown (Ce+4 ). As the hydrogen peroxide decomposes 
from the nanoparticle suspension, the observed brown color 
starts to disappear and the solution color returns to yellow 
(Ce+3 ) within ten days as shown in FIG. 9. In FIG. 9, note the 
35 
reversible and successive shift in transmittance of dextran 
coated nanoceria particles after adding hydrogen peroxide on 
day one a, % transmittance plotted against the wavelength, is 
between approximately 475 run to approximately 700 run, at 
day 2 b, % transmittance is between approximately 410 run to 
40 
approximately 600 run, day 3 c, % transmittance is between 
400 run and approximately 550 run; days 4-10 d-j, after the 
addition of hydrogen peroxide and the decomposition of 
hydrogen peroxide nears completion, the plot of the % trans-
mittance against wave length is within a narrower range 
45 
between approximately 400 run and approximately 450 run 
wavelength, confirming the disappearance of the brown color. 
Autocatalytic activity is represented Equation (1) below: 
2Ce.3(aq)+H202+2H.(aq)~2Ce+4(aq)+2H20 (1) 
in FIG. 6B, the vial on the right, with a darker solution. No 50 
precipitation of agglomeration is observed in any of the two 
solutions, showing the great stability ofthis nanoceria prepa-
ration in aqueous solution. 
FIGS. lOA-lOF are real-time images of dextran coated 
nanoceria solutions with and without hydrogen peroxide. 
FIG. lOA shows a dextran-coated nanoceria solution without 
hydrogen peroxide on the left 5 and with hydrogen peroxide 
on the right 10 at day one. FIG. lOB shows a dextran-coated 
nanoceria solution without hydrogen peroxide on the left 15 
and with hydrogen peroxide on the right 20 at day three. FIG. 
lOC shows dextran nanoceria solutions without hydrogen 
peroxide on the left 25 and with hydrogen peroxide on the 
right 30 at day seven. FIG. lOD shows dextran nanoceria 
solutions without hydrogen peroxide on the left 35 and with 
hydrogen peroxide on the right 40 at day ten. FIG. lOE shows 
dextran nanoceria solutions without hydrogen peroxide on 
the left 45 and with hydrogen peroxide on the right 50 at day 
ten after adding fresh hydrogen peroxide on the tenth day. 
Further characterization of the dextran coated nanoceria 
preparation is provided in FIGS. 7 A, 7B and 7C showing the 55 
high crystallinity of the nanoceria particles of the present 
invention. FIG. 7A is a transmission electron microscopy 
(TEM) image of the dextran coated ceria nanoparticles show-
ing the size and dispersity of the ceria crystals. FIG. 7B is a 
high resolution transmission electron microscopy (TEM) 60 
image of the dextran coated ceria nanoparticles, showing that 
the coating does not affect the crystallinity. FIG. 7C is a 
selected area electron diffraction (SAED) image of a single 
ceria crystal showing that the dextran coated ceria crystal is a 
FCC phase crystal. 65 FIG. lOF shows dextran nanoceria solutions without hydro-
gen peroxide on the left 55 and with hydrogen peroxide on the 
right 60 at day twenty. The real-time images confirm the 
Concanavalin studies were used to verify the dextran coat-
ing of the ceria nanoparticles of the present invention. 
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autocatalytic activity shown in FIG. 9; there are color changes 
as the hydrogen peroxide decomposes from contact with the 
nanoparticle suspension. 
10 
With regard to biological activity, preliminary biological 
data shows that, as expected, the dextran-coated nanoceria 
preparation act as potent antioxidant agents. In these experi-
ments, normal human cell cultures are exposed to hydrogen 
peroxide. This treatment causes a high level of cellular stress, 
similar to that experienced by cells under oxidative damage. 
The data show that in the absence of dextran nanoceria 
(DNC), from approximately 50% to approximately 95% of 
the cells died upon addition of hydrogen peroxide, whereas 
most of them survive this harsh treatment when in the pres-
ence of dextran coated nanoceria (DNC). 
presence of both Ce+3 and Ce+4 and therefore its biological 
and autocatalytic activity. As shown in FIG. 12, the presence 
ofboth Ce+3 and Ce+4 species in the aminated dextran coated 
nanoceria are similar to those obtained with non-crosslinked 
nanoceria. This indicates that crosslinking of the dextran does 
not affect the dual valency (Ce+3 /Ce+4 ) in the nanoceria 
preparation of the present invention and most likely will not 
affect its autocatalytic/antioxidant properties. Biological uses 
of the crosslinked, biodegradable polymer-coated nanoceria 
10 include administration to human and other mannnals needing 
antioxidant treatments to prolong cell life. 
FIGS. llA and llB are graphs of percent viability of 15 
normal cell cultures, cardiomyocytes and dermal fibroblast, 
respectively. In FIGS. llA and llB, the control is untreated 
and thus 100% viable; the cells treated with dextran coated 
nanoceria (DNC) are 100% viable and the cells treated with a 
combination of dextran coated nanoparticles (DNC) and 20 
hydrogen peroxide are 100% viable. However, FIG. llA 
shows that normal cell cultures of cardiomyocytes are 
approximately 5% viable when treated with or exposed to 
only hydrogen peroxide and FIG. llB shows that normal cell 
cultures of dermal fibroblasts are approximately 50% viable 25 
when treated with hydrogen peroxide without dextran coated 
ceria nanoparticles (DNC). Thus, FIGS. llA and llB are 
graphical illustrations of the effectiveness of dextran coated 
ceria nanoparticles as potent antioxidant agents that promote 
100% cell viability in the presence of deadly oxidizing 30 
agents. 
The crosslinking and amination of dextran coated ceria 
with epichlorohydrin as discussed in Example 2 above, was 
studied to determine whether the anti-oxidant properties of 
the nanoceria particles could be extended to injectable or 35 
targetable biomedical applications. 
The dextran coated nanoceria prepared according to 
Example 1 shows great stability in water and various aqueous 
buffers, such as 0.1 M phosphate buffer, pH 7.4, without 
compromising its autocatalytic and antioxidant properties. 40 
However, the surface of this nanoparticle cannot be easily 
modified with targeting ligands such as peptides, oligonucle-
otides and proteins. To advance these studies, the polymeric 
dextran coating has been crosslinked on the surface of the 
ceria nanoparticle using epichlorohydrin and further deriva- 45 
tized its surface with annnonia to yield an aminated dextran 
coated nanoceria. As discussed earlier, it is known in the art to 
use other crosslinking agents and the present invention incor-
porates by reference, other known crosslinking agents, such 
as, but not limited to, glutaraldehyde, bromide derivatives of 50 
cyanogens, and the like. 
Preliminary characterization of this preparation shows that 
indeed the dextran surface contains reactive amino groups 
that can be used to conjugate targeting ligands and various 
dyes, including near infrared dyes that would allow in vivo 55 
optical tracking of the nanoparticle. Furthermore, this amine 
group, which has a positive charge at physiological pH, can be 
reacted with a succinic anhydrate, resulting in a carboxylated 
or negatively charged nanoceria preparation, greatly expand-
ing the conjugation capabilities of the aminated preparation. 60 
FIG. 12 is an X-ray photon spectroscopy (XPS) spectrum 
of the aminated crosslinked nanoceria showing the presence 
of a mixed valence, Ce+3 and Ce+4 similar to the spectrum of 
dextran coated nanoceria that is not aminated. 
Physical properties of the aminated dextran coated nanoc- 65 
eria were analyzed by X-ray photon spectroscopy to deter-
mine whether the crosslinking procedure would affect the 
Example 3 
Carboxylated Polymer Coating ofNanoceria 
Particles 
In another embodiment, following the procedure outlined 
in Example 1, wherein under ambient conditions, a 1 molar 
solution of a polyacrylic acid is used in place of the 1 molar 
solution of dextran, nanoceria particles are coated with a 
biodegradable polymer containing a plurality of carboxylic 
groups ( carboxylated polymer), wherein a portion of the car-
boxyl groups are associated with the cerium oxide surface and 
a portion of carboxyl groups are exposed on the nanoparticle 
surface and available for conjugation. The carboxylated 
nanoparticle can be reacted with a diamine, such as ethylene 
diamine, and correspondingly converted to an amine func-
tionalized nanoparticle. 
Synthesis Method. 
The preparation of polyacrylic acid coated nanoceria 
(PAA-nanoceria) involves the use of cerium (III) nitrate and 
polyacrylic acid (PAA). 1 M cerium (III) nitrate (Aldrich, 
99%) solution(2.17 grams in 5.0milliliters (ml) ofwater)was 
mixed with 0.5 mM solution of PAA (Sigma) to form mixture 
(I). With continuous stirring, the cerium nitrate and PAA 
mixture (I), is added drop wise to 30.0 ml of29% annnonium 
hydroxide (Sigma Aldrich, 30%) solution to form mixture II. 
Subsequently, mixture (II) is stirred continuously for 24 
hours; at this point, the solution has changed from a light 
yellow to a deep brown color. Next, the stirred mixture (II) is 
centrifuged at 4000 rpm for two 30 minute cycles to settle 
down any debris and large particles. The centrifuged solution 
is then purified from free PAA by ultrafiltration using 30K 
molecular weight cut-off Amicon filter (Millipore, Inc.) The 
resulting negative charge on the PAA-nanoceria is assessed 
by zeta potential analysis. 
Below is a schematic diagram (2) of the synthesis ofpoly-






NJLiOH -24 hrs (2) 
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Note that the nanoparticles are functionalized with car-
boxylic groups on the surface, which allows conjugation of 
peptides, DNA oligonucleotides, proteins, antibodies and 
small molecules for targeting applications, without the need 
for cross-linking the polymer. 
12 
the creation of targeted molecular imaging agent for MRI as 
reported in Gaw et al. U.S. Patent Publication 2003/0124, 194; 
the teaching with regard to use of carboxylated polymers is 
incorporated herein by reference. 
Some dextran coated iron oxide nanoparticles have been 
approved by the FDA for various applications including MRI 
imaging oflymphnodes as reported by M. G. Harisinghani, et 
al. in New England Jl. of Medicine 2003, 348, 2491. 
Furthermore, the carboxylic groups on the polyacrylic acid 
nanoceria can be converted to reactive amine groups by the 
reaction with a water soluble diamine, such as ethylene 
diamine, in the presence of a water soluble carbodiimide as 
disclosed in Gaw et al., U.S. Patent Publication 2002/ 
0124194 for coating of iron oxide nanoparticles as MRI con-
trast agents. 
PAA-nanoceria possess similar autocatalytic activity as 
regular, non-coated nanoceria, dextran coated nanoceria, and 
aminated dextran coated nanoceria. In addition, PAA-nano-
ceria contains both Ce4 + and Ce3 + (mixed valance) on the 
nanoparticle which is important for its autocatalytic and anti-
oxidant activity as shown in FIG.13. The X-ray photon spec-
troscopy (XPS) image of polyacrylic acid coated nanoceria 
(PAA-nanoceria) in FIG. 13 is substantially similar to the 
X-ray photon spectroscopy (XPS) image of dextran coated 
nanoceria and aminated dextran coated nanoceria shown in 
FIG. 12. This indicates that the PAA-nanoceria will behave 
like the other polymer coated nanoceria preparations dis-
closed herein. 
The newly developed synthesis of biodegradable polymer 
10 coated ceria nanoparticles presented herein would be ideal for 
clinical applications and a candidate for FDA approval. It was 
an unexpected finding that the physical properties of the 
biodegradable polymer coated ceria nanoparticles remain 
15 
unaffected by the polymeric coating which substantially 
improves handling and application for antioxidant and auto-
catalytic biomedical applications. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
20 modifications which it has presumed in practice, the scope of 
the invention is not intended to be, nor should it be deemed to 
be, limited thereby and such other modifications or embodi-
ments as may be suggested by the teachings herein are par-
ticularly reserved especially as they fall within the breadth 
25 and scope of the claims here appended. 
We claim: 
Prior to the present invention, a facile, cost effective, non-
toxic synthesis of biodegradable polymer coated nanoceria 
particles was not available. The synthesis does not require 
surfactants or vigorous experimental conditions and the end-
product is suitable for unlimited biomedical applications. 
Prior to the present invention, it was not known that a 
biodegradable polymeric coating of ceria nanoparticles 
would not affect the autocatalytic and antioxidant properties 
1. A method for the synthesis of a plurality of polymer-
coated cerium oxide nanoparticles coated with a biodegrad-
30 able polymer for antioxidant, free-radical scavenger and 
autocatalytic biomedical applications, comprising the steps 
of: 
of the ceria nanoparticles. 
A biodegradable polymer coated nanoceria exhibits good 35 
solubility and stability in water and phosphate buffer saline. 
The preparation has good stability over many days in the 
buffer solutions which is advantageous over the preparations 
which aggregate when redispersed in aqueous media. This 
characteristic makes them suitable for biomedical applica- 40 
tions and clinical use. Further, there is no problem with 
agglomeration in aqueous solution over a long period of time, 
as with preparations using a sol-gel technique as reported by 
H. S. Potdar et al. in Materials Chemistry and Physics, 2002 
74, 306. 
Further advantages of the biodegradable polymer coated 
cerium oxide nanoparticle include a suspension that can be 
concentrated using ultrafiltration devices without agglomera-
tion of the nanoparticles. 
45 
With regard to the second embodiment, the dextran coating 50 
on the nanoparticle can be crosslinked with epichlorohydin 
and ammonia, resulting in an aminated dextran coated ceria 
nanoparticles. The major benefit of the crosslinked dextran 
coating is the ability to form conjugates to various ligands, 
such as peptides, antibodies, DNA-oligonucleotides, proteins 55 
and small molecules, to create a targetable ceria nanoparticle. 
This would allow targeting or "homing" of the nanoparticle to 
the corresponding site of inflammation or disease. 
All embodiments of the present invention are useful in 
forming colloidal compositions which include nanoparticle 60 
suspensions of cerium oxide coated with a biodegradable 
polymer. The resulting colloidal composition is highly stable 
a) preparing an aqueous cerium nitrate solution containing 
approximately 2.0 to approximately 3 .0 grams of cerium 
nitrate to approximately 5 ml of water; 
b) mixing the aqueous cerium nitrate solution with a bio-
degradable polymer to form mixture (I); 
c) adding mixture (I) dropwise to an armnonium hydroxide 
solution while continuously stirring to form mixture (II); 
d) centrifuging the mixture (II) containing armnonium 
hydroxide to settle any debris or large particles; 
e) purifying the centrifuged mixture of d) by ultrafiltration; 
f) recovering a plurality of non-agglomerated, polymer-
coated cerium oxide nanoparticles coated with the bio-
degradable polymer wherein the plurality of polymer-
coated cerium oxide nanoparticles has a UV profile 
exhibiting strong absorption below approximately 400 
nm with peak absorption at approximately 300 nm; and 
g) contacting isolated biological cells with the plurality of 
polymer-coated cerium oxide nanoparticles wherein the 
antioxidant, free-radical scavenging and autocatalytic 
properties of the polymer-coated cerium oxide nanopar-
ticles are unchanged from uncoated cerium oxide nano-
particles. 
2. The method of claim 1, wherein the biodegradable poly-
mer is selected from the group consisting of a carbohydrate 
polymer, a synthetic polyol, a carboxylated polymer, and 
derivatives thereof. 
3. The method of claim 2, wherein the carboxylated poly-
mer is polyacrylic acid. 
4. The method of claim 2, wherein the carboxylated poly-
mer is reacted with a diamine selected from at least one of 
ethylene diamine, propylene diamine and hexane diamine, to 
provide an aminated cerium oxide nanoparticle in a reaction 
in water and water-based buffers, such as phosphate saline 
buffer and the like. The colloidal compositions are also suit-
able for concentration and sterilization by filtration. 65 that eliminates the need for polymer crosslinking. 
Similar procedures have been used in the preparation of 
carboxylated coated iron oxide nanoparticles, allowing for 
5. The method of claim 2, wherein the carbohydrate poly-
mer is a polysaccharide. 
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6. The method of claim 5, wherein the polysaccharide is 
selected from the group consisting of dextran, arabinogalac-
tan and chitosan. 
7. The method of claim 6, wherein the polysaccharide is 
dextran. 
8. A composition of matter that is useful as a potent anti-
oxidant in biomedical applications that comprises: 
14 
polyol, a carboxylated polymer, and derivatives thereof 
wherein the plurality of crosslinked-animated polymer-
coated cerium oxide nanoparticles has a UV profile 
exhibiting strong absorption below approximately 400 
nm with peak absorption at approximately 300 nm and 
the antioxidant, free-radical scavenging and autocata-
lytic properties of the polymer-coated cerium oxide 
nanoparticles are unchanged from uncoated cerium 
oxide nanoparticles. 
18. The composition of claim 17, wherein the carbohydrate 
polymer is a polysaccharide. 
19. The composition of claim 18, wherein the polysaccha-
ride is selected from the group consisting of dextran, ara-
binogalactan and chitosan. 
20. The composition of claim 19, wherein the polysaccha-
ride is dextran. 
a plurality of polymer-coated nanoceria particles in contact 
with isolated biological cells wherein the plurality of 
polymer-coated nanoceria particles is coated with a bio- 10 
degradable polymer selected from at least one of a car-
bohydrate polymer, a synthetic polyol, a carboxylated 
polymer, and derivatives thereof wherein the plurality of 
polymer-coated cerium oxide nanoparticles has a UV 
profile exhibiting strong absorption below approxi- 15 
mately 400 nm with peak absorption at approximately 
300 nm and the antioxidant properties of the polymer-
coated cerium oxide nanoparticles are unchanged from 
uncoated cerium oxide nanoparticles. 
21. The composition of claim 20, wherein the plurality of 
dextran-coated cerium oxide nanoparticles has a UV profile 
exhibiting strong absorption below approximately 400 nm 
20 with peak absorption at approximately 300 nm. 9. The composition of claim 8, wherein the carboxylated 
polymer is polyacrylic acid and derivatives thereof. 
10. The composition of claim 8, wherein the carbohydrate 
polymer is a polysaccharide and derivatives thereof. 
22. The composition of claim 20, wherein the physical 
properties of the dextran-coated cerium nanoparticles repli-
cate the physical properties of the uncoated nanoceria par-
ticles for therapeutic applications as an antioxidant, free-11. The composition of claim 10, wherein the polysaccha-
ride is selected from the group consisting of dextran, ara-
binogalactan, chitosan and derivatives thereof. 
25 radical scavenger and autocatalytic agent. 
12. The composition of claim 11, wherein the polysaccha-
ride is dextran and derivatives thereof. 
23. The composition of claim 20, wherein the plurality of 
dextran-coated cerium oxide nanoparticles form a colloidal 
suspension that is stable in water. 
13. The composition of claim 12, wherein the plurality of 
dextran-coated cerium oxide nanoparticles has a UV profile 
exhibiting strong absorption below approximately 400 nm 
with peak absorption at approximately 300 nm. 
24. The composition of claim 20, wherein the plurality of 
30 dextran-coated cerium oxide nanoparticles form a colloidal 
suspension that is stable in a phosphate buffer saline solution. 
25. A composition of matter that is useful as an antioxidant, 
free-radical scavenger and autocatalyst in biomedical appli-
cations that comprises: 
14. The composition of claim 12, wherein the physical 
properties of the dextran-coated cerium nanoparticles repli-
cate the physical properties of the uncoated nanoceria par- 35 
ticles for therapeutic applications as an antioxidant, free-
radical scavenger and autocatalytic agent. 
15. The composition of claim 12, wherein the plurality of 
dextran-coated cerium oxide nanoparticles form a colloidal 
suspension that is stable in water. 
16. The composition of claim 12, wherein the plurality of 
dextran-coated cerium oxide nanoparticles form a colloidal 
suspension that is stable in a phosphate buffer saline solution. 
40 
17. A composition of matter that is useful as an antioxidant, 
free-radical scavenger and autocatalyst in biomedical appli- 45 
cations that comprises: 
a plurality of polymer-coated nanoceria particles in contact 
with isolated biological cells wherein the plurality of 
polymer-coated nanoceria particles is coated with a 
crosslinked-aminated biodegradable polymer selected 50 
from at least one of a carbohydrate polymer, a synthetic 
a plurality of polymer-coated nanoceria particles in contact 
with mammalian cells in need of antioxidant treatments 
to prolong cell life wherein the plurality of polymer-
coated nanoceria particles is coated with a crosslinked-
aminated biodegradable polymer selected from at least 
one of a carbohydrate polymer, a synthetic polyol, a 
carboxylated polymer, and derivatives thereof wherein 
the plurality of crosslinked-animated polymer-coated 
cerium oxide nanoparticles has a UV profile exhibiting 
strong absorption below approximately 400 nm with 
peak absorption at approximately 300 nm and the anti-
oxidant, free-radical scavenging and autocatalytic prop-
erties of the polymer-coated cerium oxide nanoparticles 
are unchanged from uncoated cerium oxide nanopar-
ticles. 
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